R D Schoenwald, C F Barfknecht, S Shirolkar, E Xia
文献索引:Life Sci. 56(15) , 1275-85, (1995)
全文:HTML全文
Sigma receptor antagonists have been proposed as leading clinical candidates for use in various psychotic disorders. Prior to clinical testing, it is imperative that a new agent be correctly identified as an antagonist and not an agonist since the latter may worsen the psychosis. For sigma-ligands many behavioral and pharmacological assays have been developed in an attempt to classify agonist/antagonist activity. These assays evaluate a response or a behavior in an animal model that can be related to clinical efficacy. However, is the action by the presumed antagonist a consequence of sigma-receptor activity? Previously we have identified sigma-receptors in acinar cells of the main lacrimal gland of the New Zealand white rabbit and have measured protein release after the addition of various N,N-disubstituted phenylalkylamine derivatives known to be sigma-ligands by receptor binding studies. Although protein release from acinar cells has been attributed to either muscarinic or alpha-adrenergic stimulation, protein release from sigma-receptor stimulation was also confirmed. In the reported studies here, we isolated and incubated acinar cells with varying concentrations of known sigma-ligands and measured protein concentration. A knowledge of the receptor profile for the disubstituted phenylalkylamines permitted experiments to be designed in which various alpha, muscarinic, serotonergic, and dopaminergic antagonists could be added in equimolar concentrations. Under the conditions of these experiments, statistically significant increases in protein release for sigma-ligands could be attributed to stimulation of sigma-receptors. Haloperidol, an apparent sigma-antagonist, caused a statistically significant decrease in protein release and also inhibited protein release when tested with a known sigma-ligand, AF2975 [N,N-dimethyl-2-phenylethylamine]. In this system, stimulation and inhibition of protein release were defined as agonist and antagonist behavior, respectively. Of particular interest were the results for BMY14802 and +/- pentazocine, both of which were found to be agonists. Various antipsychotic and antidepressant drugs were measured for their agonist/antagonist behavior. Because of multireceptors present in acini, their agonist or antagonist behaviour could not be attributed solely to interaction with the sigma-receptor unless specific antagonists were added.
结构式 | 名称/CAS号 | 分子式 | 全部文献 |
---|---|---|---|
![]() |
N,N-二甲基-2-苯乙胺
CAS:1126-71-2 |
C10H15N |
Structure–activity correlations for β-phenethylamines at hum...
2008-01-01 [Bioorg. Med. Chem. 16 , 7415-23, (2008)] |
Dissociative energy flow, vibrational energy redistribution,...
2010-10-28 [J. Phys. Chem. A 114(42) , 11078-84, (2010)] |
[Development of positron tracer for in vivo estimation of br...
1984-06-01 [Kaku Igaku. 21(6) , 671-8, (1984)] |
The role of tear proteins in tear film stability in the dry ...
1998-01-01 [Adv. Exp. Med. Biol. 438 , 391-400, (1998)] |
Kinetics of [11C]N,N-dimethylphenylethylamine in mice and hu...
1987-06-01 [J. Nucl. Med. 28(6) , 1006-11, (1987)] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved